Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Bispecific AFM13 plus pembro for R/R Hodgkin lymphoma

Stephen Ansell • 2 Jul 2019
ICML 2019
Hodgkin Lymphoma Lymphoma AFM13 Antibodies Checkpoint inhibitors Pembrolizumab

AFM13 is a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Here Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the trial of AFM13 plus pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure (NCT02665650). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Stephen Ansell

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
1:03
What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell • 11 Dec 2023
0:51
Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell • 11 Dec 2023
1:21
Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals